Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM)

Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)

“…In 11 studies treatment was specifically used for headache prevention [12, 29–38], in 8 studies treatment effect on headache was evaluated in women who required treatment for contraception or medical reasons [13–15, 39–43], in 2 studies it was not specifically stated if treatment was prescribed specifically for headache treatment or for other indications [44, 45]. Five studies were performed in women with MO or MA not necessarily related to menstruation [12–14, 41, 43], 10 in MRM or MM [29–39, 43, 45], 4 in PMM [29, 35, 38, 39], and 2 in women with and without headache [15, 40].…”

“…Five studies were performed in women with MO or MA not necessarily related to menstruation [12–14, 41, 43], 10 in MRM or MM [29–39, 43, 45], 4 in PMM [29, 35, 38, 39], and 2 in women with and without headache [15, 40]. …”

New and emerging contraceptive options: a focus on transdermal contraception

“…A systematic literature review found no negative influence on bone mineral density, although stated that data are very limited for the skin patch. 19 A randomized study examined 20 women using the patch containing 20 µg of ethinylestradiol and 150 µg of norelgestromin and 20 women using the vaginal ring, with 20 women without hormonal contraception serving as healthy controls. Parameters for bone turnover were measured every 3 months for one year, and bone mineral density was measured by dual energy X-ray absorptiometry at baseline and after 12 months.…”

Migraine et contraception

“…1. Choix de la contraception en fonction de la maladie migraineuse et de son é volution [28][29][30]36,39,41,[45][46][47]. FDR : facteur de risque ; COP : contraception oestroprogestative, EE : é thinylestradiol, E2 : oestradiol ; facteurs de risque vasculaires arté riels : âge 35 ans, tabagisme, HTA, diabè te, obé sité , dyslipidé mie, les anté cé dents familiaux d'infarctus cé ré bral et/ou d'infarctus du myocarde et/ou de mort subite avant 55 ans chez un apparenté du 1 er degré de sexe masculin ou avant 65 ans chez un apparenté du 1 er degré de sexe fé minin.…”

“…Les oestrogè nes naturels auraient thé oriquement en effet un impact plus favorable sur le mé tabolisme glucidique et lipidique et donc potentiellement sur le risque cardio-vasculaire en comparaison à l'EE. L'effet des oestrogè nes naturels dans les COP a é té é tudié de maniè re prospective par Nappi et al [46], chez des patientes pré sentant des migraines lié es aux rè gles n'ayant jamais utilisé de COP (n = 18) et chez des patientes ayant pré alablement utilisé s des COP avec EE (n = 14). L'utilisation d'un COP combinant valé rate d'oestradiol et dié nogest a é té associé e dans les 2 groupes à une diminution de la fré quence des crises, de la duré e des crises et progressivement de l'intensité jusqu'à la fin des 6 cycles é tudié s ainsi qu'une diminution de la consommation d'analgé siques [46].…”